RELEASE: TREAT-NMD and Aetion Announce Real-World Testing Partnership

(Information sent by the signatory company).

RELEASE: TREAT-NMD and Aetion Announce Real-World Testing Partnership

(Information sent by the signatory company)

- TREAT-NMD, one of the world's leading neuromuscular disease registry networks, and Aetion announce partnership on real-world testing

The collaboration will leverage global patient registries to provide real-world evidence on rare neuromuscular diseases to biopharmaceutical companies.

NEW YORK and NEWCASTLE, England, Feb. 22, 2023 /PRNewswire/ -- TREAT-NMD Services Ltd, the trading arm of TREAT-NMD Alliance Ltd, a charity focused on neuromuscular disorders, and Aetion, Inc., the leading world in real-world testing technology and analysis (RWE), today announced a three-year global partnership agreement that will see organizations work on a series of projects to accelerate the development of treatment solutions for people with rare neuromuscular diseases, such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy, Charcot and Becker muscular dystrophy.

Accessing high-quality, structured medical data and patient experience registries, and the subsequent generation of scientifically rigorous, regulatory-grade RWEs, presents a unique set of challenges for researchers in the field of rare neuromuscular diseases. These projects will combine the expertise of the TREAT-NMD Global Registry Network, which collects de-identified data from patients around the world, with Aetion's regulatory-grade expertise in RWE study design and analysis.

"TREAT-NMD is pleased to partner with Aetion on a variety of projects to generate the scientific evidence needed to develop and deliver novel treatment solutions to people with neuromuscular diseases around the world," said David Allison, CEO of TREAT-NMD. . "We will work together to ensure that researchers have access to rare disease data while leveraging Aetion's trusted RWE capabilities."

As globally recognized partners, TREAT-NMD and Aetion strive to drive impact by accelerating the delivery of rapid and robust RWE for the highly challenging area of ​​rare neuromuscular diseases. In turn, this collaboration will support solutions for biopharmaceutical researchers by enabling easier access to critical rare disease data sources and scientifically validated study design guided by world-class RWE methodologies.

"Aetion is inspired by TREAT-NMD's mission to operate a collaborative and inclusive global network and data infrastructure to advance the diagnosis, treatment and care of neuromuscular patients globally," said Nicolas Deltour, Vice President of Real World Solutions at Aetion. "The richness of the TREAT-NMD registry network combined with Aetion's RWE analytical technology and expertise will play a critical role in supporting pharmaceutical companies in advancing treatments and better outcomes for neuromuscular patients in Europe and abroad. everyone".


TREAT-NMD is a network for the neuromuscular field that provides an organizational infrastructure to support each stage of the drug development process to ensure that the most promising new therapies reach patients as quickly as possible. Since its launch in January 2007, the network's focus has been on developing tools that industry, clinicians, and scientists need to bring new therapeutic approaches through preclinical development and into the clinic, and establishing the best practice of care for neuromuscular patients worldwide. Learn more at or follow us @treat_nmd.

About Aetion

Aetion is a healthcare analytics company that provides real-world evidence for manufacturers, buyers and regulators of medical technologies and treatments. The Aetion Evidence Platform® analyzes real-world data to produce scientifically validated, rapid, and transparent answers about safety, efficacy, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs the most critical healthcare decisions—what works best, for whom, and when—to guide the product development, marketing and payments innovation. Learn more at and follow us @aetioninc.

Logo -

Logo -

View original content: